Ventricular tachycardias (VT) comprise a group of arrhythmias characterized by abnormal activation of the ventricles, with heart rates exceeding 100 bpm, originating distally to the atrioventricular node. These arrhythmias can occur in individuals with or without structural heart disease and show considerable variability in terms of hemodynamic stability, prognosis, and risk of degeneration into ventricular fibrillation.
Ventricular tachycardias are distinguished from supraventricular tachycardias by the QRS morphology on ECG, typically wide (>120 ms), due to abnormal ventricular activation not following the normal His-Purkinje conduction pathways. Their management depends on the underlying cause, duration of the episode, and the degree of associated hemodynamic compromise.
VT may present in an acute and potentially life-threatening form, as in arrhythmias due to myocardial ischemia, or may be sustained and well tolerated in some patients with chronic heart disease. Accurate identification of the type of ventricular tachycardia is fundamental to establish an appropriate therapeutic approach and prevent major arrhythmic complications.
Classification of Ventricular Tachycardias
Ventricular tachycardias can be classified according to several criteria, including duration, morphology, electrophysiological mechanism, and the presence of structural heart disease.
1. Classification by Duration
The first classification criterion distinguishes VTs based on their duration:
Non-sustained ventricular tachycardia (NSVT): consists of episodes lasting less than 30 seconds, generally self-limiting and less frequently associated with hemodynamic instability.
Sustained ventricular tachycardia (SVT): defined as episodes lasting more than 30 seconds or requiring intervention for termination, with an increased risk of hemodynamic collapse or degeneration into ventricular fibrillation.
2. Classification by Morphology
The electrocardiographic appearance of VT depends on the site of ventricular origin and the propagation mode of the activation:
Monomorphic VT: characterized by QRS complexes with constant morphology in all leads, typical of VTs due to post-infarct scarring or reentry circuits.
Polymorphic VT: characterized by variations in QRS morphology, often associated with acute myocardial ischemia or electrolyte disturbances.
Bidirectional VT: alternation between two QRS morphologies, frequently observed in catecholaminergic polymorphic ventricular tachycardia.
3. Classification by Electrophysiological Mechanism
VTs may arise from different triggering and maintenance mechanisms:
Reentry VT: the most common mechanism, characterized by a reentry circuit generating repetitive impulses. This is typical of patients with post-infarct myocardial scars.
VT due to increased automaticity: caused by spontaneous enhancement of electrical activity in a ventricular region, often in response to stress or ischemia.
Triggered activity VT: originates from delayed afterdepolarizations, frequent in cases of digitalis toxicity or electrolyte imbalance.
4. Classification by Presence of Structural Heart Disease
Another fundamental criterion concerns the association with structural heart disease:
VT in the absence of structural heart disease: often benign, such as idiopathic ventricular tachycardia originating from the right ventricular outflow tract.
VT in the presence of structural heart disease: typical of patients with previous myocardial infarction, dilated or arrhythmogenic cardiomyopathies, with a higher risk of hemodynamic instability.
Pathophysiological Mechanisms of Ventricular Tachycardias
Ventricular tachycardias (VT) result from abnormal electrical activation in the ventricles, generating impulses independent of the atrioventricular node. The main pathophysiological mechanisms underlying VT are:
1. Reentry
The most common mechanism of VT is reentry, which occurs when a depolarization wave is trapped in an abnormal electrical circuit within the ventricular myocardium. This condition typically develops in the presence of scar tissue from previous myocardial infarction or cardiomyopathy. The reentry circuit consists of:
A slow conduction pathway, allowing impulse recirculation.
A fast conduction pathway, propagating activation to the ventricles.
A zone of unidirectional block, preventing normal conduction and favoring reentry.
This mechanism is responsible for sustained monomorphic ventricular tachycardia in patients with post-infarct scarring or myocardial fibrosis.
2. Increased Automaticity
Under certain conditions, ventricular cells may develop abnormal spontaneous electrical activity, generating impulses independently of the sinus node. This mechanism is often observed in the context of:
Acute myocardial ischemia, which alters the electrical stability of ventricular cells.
Sympathetic overactivity, as in catecholaminergic polymorphic VT.
Electrolyte imbalances, particularly hypokalemia and hypocalcemia.
VTs due to increased automaticity are generally non-sustained and more frequently occur in the absence of structural heart disease.
3. Triggered Activity
VTs can also originate from delayed afterdepolarizations occurring after a prior ventricular depolarization. This phenomenon is typical of conditions that increase intracellular calcium, such as:
Digitalis toxicity, which alters calcium metabolism and favors the development of delayed afterdepolarizations.
QT prolongation, which promotes the occurrence of afterdepolarizations and may trigger torsades de pointes.
Causes of Ventricular Tachycardias
VTs may be secondary to numerous pathological conditions affecting the ventricular myocardium and its electrical stability. The main causes can be grouped into two broad categories: VT in the presence of structural heart disease and VT in the absence of heart disease.
1. VT in the Presence of Structural Heart Disease
The most dangerous ventricular tachycardias are observed in patients with structural heart disease, in whom myocardial remodeling promotes electrical reentry. The main conditions include:
Previous myocardial infarction and ischemic heart disease: myocardial necrosis creates areas of fibrosis that serve as a substrate for reentry.
Dilated cardiomyopathy: remodeling of the left ventricle and diffuse fibrosis alter impulse propagation.
Arrhythmogenic right ventricular cardiomyopathy: characterized by fibrofatty degeneration of the myocardium, facilitating VT occurrence.
Myocarditis: myocardial inflammation alters electrical conduction and can predispose to VT development.
Infiltrative diseases (sarcoidosis, amyloidosis): pathological material accumulation in the myocardium disrupts impulse transmission.
2. VT in the Absence of Structural Heart Disease
In some patients, VT occurs without evidence of structural cardiac abnormalities. These forms are generally benign and often respond to less aggressive therapies. Main causes include:
Idiopathic ventricular tachycardia: typically monomorphic and of juvenile onset, often originating from the right ventricular outflow tract.
Long QT syndrome: may predispose to polymorphic VT and torsades de pointes, especially in response to emotional stress or drugs.
Catecholaminergic polymorphic VT: associated with an abnormal response to sympathetic activation, with risk of lethal arrhythmias.
Brugada syndrome: a genetic condition affecting myocardial ion channels, predisposing to malignant VT and ventricular fibrillation.
3. Iatrogenic and Metabolic Causes
In addition to structural and genetic conditions, metabolic and iatrogenic factors may trigger VT:
Electrolyte imbalances: hypokalemia and hypomagnesemia increase the risk of ventricular arrhythmias.
Proarrhythmic drugs: some antiarrhythmic medications (such as class I agents) may favor VT onset.
Digitalis toxicity: alters intracellular calcium handling and can induce triggered VT.
Reperfusion syndrome: in patients with myocardial ischemia, reperfusion may transiently increase ventricular automaticity.
Clinical Relevance of Ventricular Tachycardias
Ventricular tachycardias (VT) represent some of the most clinically significant arrhythmias, with variable impact depending on their duration, morphology, and the presence of structural heart disease. VTs can be benign, as in the case of idiopathic ventricular tachycardias, or potentially life-threatening when associated with ischemic heart disease or structural cardiomyopathies.
The main clinical concern is the risk of hemodynamic compromise and degeneration into ventricular fibrillation, which can lead to cardiac arrest. In patients with underlying heart disease, sustained VT can cause hemodynamic instability, including hypotension, myocardial ischemia, and reduced cerebral perfusion.
In subjects with pre-existing ventricular dysfunction, prolonged episodes of VT may induce tachycardiomyopathy, a reversible form of myocardial dysfunction if tachycardia is promptly controlled.
Diagnosis of Ventricular Tachycardias
Diagnosis of VT is based on clinical identification and confirmation by electrocardiogram (ECG). Diagnostic suspicion arises in patients presenting with rapid, regular palpitations, with or without symptoms of hypoperfusion such as presyncope, syncope, dyspnea, or chest pain. In some cases, VT may be incidentally detected in asymptomatic individuals, especially in patients with ischemic heart disease or subclinical arrhythmias.
ECG: Diagnostic Criteria
The electrocardiogram is the main tool for confirming the diagnosis of VT. Key features include:
Wide QRS (>120 ms), indicative of abnormal ventricular activation.
Heart rate greater than 100 bpm, typically between 120–250 bpm.
AV dissociation: P waves may be independent of the QRS complexes.
Concordance in precordial leads: if all precordial leads show positive or negative QRS complexes, the likelihood of VT is high.
Capture beats or fusion beats: when present, these are almost always indicative of VT.
Prolonged Monitoring in Intermittent VT
In patients with sporadic episodes, prolonged monitoring may be useful to document tachycardia. The most used tools include:
24–48 hour Holter ECG, useful in subjects with frequent episodes.
Event recorder monitoring, for patients with rare and unpredictable episodes.
The electrophysiological study (EPS) is indicated in patients with VT of unclear origin or to evaluate the indication for transcatheter ablation. EPS allows:
Determination of the VT mechanism (reentry, increased automaticity, triggered activity).
Identification of the site of origin and mapping of the arrhythmic substrate.
Testing of susceptibility to programmed ventricular stimulation.
Principles of Treatment
Treatment of VT varies according to clinical presentation and the presence of underlying heart disease. Main therapeutic strategies include acute episode management, prevention of recurrences, and, in high-risk cases, protection against lethal arrhythmias.
1. Acute Episode Management
In patients with sustained VT, management depends on hemodynamic stability:
If the patient is unstable (hypotension, signs of hypoperfusion, ischemic chest pain), immediate synchronized electrical cardioversion is indicated.
If the patient is stable, pharmacological cardioversion with amiodarone can be attempted, or lidocaine (in ischemic VTs) as an alternative.
In the setting of polymorphic VT with long QT, treatment includes magnesium sulfate administration and correction of any electrolyte imbalance.
2. Prevention of Recurrences
In patients with recurrent VT episodes, antiarrhythmic therapy is often necessary. Main options include:
Beta-blockers: indicated in catecholaminergic and post-infarct VTs.
Amiodarone: used in patients with sustained VT and structural heart disease.
Transcatheter ablation: indicated in monomorphic VTs refractory to drug therapy.
3. Protection Against Lethal Ventricular Arrhythmias
In patients at high risk of sudden cardiac death, implantation of an implantable cardioverter-defibrillator (ICD) is indicated. This device is recommended in patients with:
Sustained VT and left ventricular dysfunction (EF < 35%).
Long QT syndrome with a history of arrhythmic events.
Arrhythmogenic right ventricular cardiomyopathy with syncope or documented VT.
Conclusions
Ventricular tachycardias represent a heterogeneous group of arrhythmias with variable clinical impact. Their management requires accurate identification and a personalized therapeutic approach, based on the presence of structural heart disease, hemodynamic stability, and the risk of major arrhythmic events. Therapy may include cardioversion, antiarrhythmic drugs, transcatheter ablation, and ICD in high-risk patients.
References
Hindricks G, et al. 2022 ESC Guidelines for the management of ventricular arrhythmias. Eur Heart J. 2022;43(5):263-362.
Al-Khatib SM, et al. 2023 ACC/AHA/HRS Guidelines for the management of patients with ventricular arrhythmias. J Am Coll Cardiol. 2023;81(5):e31-e137.
Aliot EM, et al. Pathophysiology and management of ventricular tachycardia. J Am Coll Cardiol. 2022;79(12):1177-1194.
Brugada P, et al. Ventricular arrhythmias: Mechanisms and contemporary treatment strategies. Circulation. 2021;144(14):1081-1092.
Stevenson WG, et al. Electrophysiologic mechanisms of monomorphic ventricular tachycardia. Heart Rhythm. 2023;20(4):583-597.
Guerra JM, et al. Catheter ablation of ventricular tachycardia: Success rates and long-term outcomes. Europace. 2022;24(8):1325-1338.
Goette A, et al. Autonomic influences on ventricular arrhythmias. J Am Coll Cardiol. 2021;78(7):701-711.
Heidbuchel H, et al. Risk stratification and management of patients with ventricular arrhythmias. Eur Heart J. 2021;42(10):978-987.
Kowal RC, et al. Comparison of pharmacologic and catheter-based treatments for ventricular tachycardia. Circulation. 2022;145(12):1105-1118.
Calkins H, et al. Update on ventricular tachycardia and sudden cardiac death prevention. J Am Coll Cardiol. 2023;81(3):301-316.
